#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 25, 2023



## **OPTION CARE HEALTH, INC.**

(Exact name of registrant as specified in its charter)

<u>Delaware</u>

(State or other jurisdiction of incorporation)

<u>001-11993</u> (Commission File Number) 05-0489664 (IRS Employer Identification Number)

3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015 (Address of principal executive offices)

<u>(312) 940-2443</u>

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol(s)	Name of each exchange on which registered			
Common Stock, \$0.0001 par value per share	OPCH	Nasdaq Global Select Market			

#### Item 2.02. Results of Operations and Financial Condition.

On October 25, 2023, Option Care Health, Inc. issued a press release reporting its third quarter 2023 financial results. A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.

The press release includes certain non-GAAP financial measures described therein. Reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

#### Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.Description99.1Press release dated October 25, 2023

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **Option Care Health, Inc.**

Date: October 25, 2023

By: /s/ Michael Shapiro

Michael Shapiro Chief Financial Officer

Exhibit 99.1



## OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2023

**BANNOCKBURN, IL., October 25, 2023** - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2023.

# Third Quarter 2023 Financial Results and Highlights

- Net revenue of \$1,093.0 million, up 7.1% compared to \$1,020.9 million in the third quarter of 2022
- Gross profit of \$254.3 million, or 23.3% of net revenue, up 16.6% compared to \$218.0 million, or 21.4% of net revenue, in the third quarter of 2022
- Net income of \$56.3 million, or \$0.31 basic earnings per share, up 45.0% compared to net income of \$38.8 million, or \$0.21 basic earnings per share, in the third quarter of 2022
- Adjusted EBITDA of \$109.8 million, up 28.2% compared to \$85.6 million in the third quarter of 2022
- Cash flow from operations of \$61.0 million compared to \$87.0 million in the third quarter of 2022
- Cash and cash equivalents balance was \$386.5 million at the end of the third quarter of 2023

John C. Rademacher, Chief Executive Officer, commented, "The Option Care Health team continues to execute on outstanding clinical outcomes and extraordinary patient care, which helped translate into solid financial results in the third quarter. I am excited to build on this momentum as we close out the year and look forward to seeing the impact we believe the team will make in the post-acute and ambulatory setting in the years to come."

## **Updated Full Year 2023 Financial Guidance**

For the full year 2023, Option Care Health expects to generate:

- Net revenue of \$4.23 billion to \$4.28 billion
- Adjusted EBITDA of \$420 million to \$425 million
- Cash flow from operations of at least \$350 million, inclusive of the Amedisys merger termination fee net of merger-related expenses

Additionally, the Company anticipates an effective tax rate of approximately 27% and net interest expense of approximately \$52.0 million to \$54.0 million.

# **Conference Call**

Option Care Health will host a conference call to discuss its third quarter 2023 financial results later today at 8:30 a.m. EDT. The conference call can be accessed via a live audio webcast that will be available online at https://investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

# **About Option Care Health**

Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at <u>OptionCareHealth.com</u>.

## **Investor Contacts**

Mike Shapiro Chief Financial Officer T: (312) 940-2538 <u>mike.shapiro@optioncare.com</u> Bob East, Asher Dewhurst, Jordan Kohnstam Westwicke T: (413) 213-0500 <u>optioncarehealth@westwicke.com</u>

## Forward-Looking Statements - Safe Harbor

This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly

update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

## Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or

a measure of the Company's liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long-lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health's business operations and facilitates comparisons to the Company's historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.

### OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)(UNAUDITED)

	Septer	mber 30, 2023	December 31, 2022			
ASSETS						
CURRENT ASSETS:						
Cash and cash equivalents	\$	386,489	\$	294,186		
Accounts receivable, net		382,957		377,542		
Inventories		251,366		224,281		
Prepaid expenses and other current assets		95,473		98,330		
Total current assets		1,116,285		994,339		
NONCURRENT ASSETS:						
Property and equipment, net		107,960		108,321		
Intangible assets, net		20,868		22,371		
Referral sources, net		323,126		341,744		
Goodwill		1,540,246		1,533,424		
Other noncurrent assets		135,131		112,737		
Total noncurrent assets		2,127,331		2,118,597		
TOTAL ASSETS	\$	3,243,616	\$	3,112,936		
LIABILITIES AND STOCKHOLDERS' EQUITY						
CURRENT LIABILITIES:						
Accounts payable	\$	429,536	\$	378,763		
Other current liabilities		194,548		186,588		
Total current liabilities		624,084		565,351		
NONCURRENT LIABILITIES:						
Long-term debt, net of discount, deferred financing costs and current portion		1,057,016		1,058,204		
Other noncurrent liabilities		122,433		103,278		
Total noncurrent liabilities	· · · · · · · · · · · · · · · · · · ·	1,179,449		1,161,482		
Total liabilities		1,803,533		1,726,833		
		1 440 092		1 296 102		
STOCKHOLDERS' EQUITY	¢	1,440,083	¢	1,386,103		
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$	3,243,616	\$	3,112,936		

### OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)

	Th	Three Months Ended September 30,			Nine Months Ended September 30,			
		2023		2022		2023		2022
NET REVENUE	\$	1,093,014	\$	1,020,918	\$	3,177,934	\$	2,917,522
COST OF REVENUE		838,748		802,917		2,443,834		2,281,685
GROSS PROFIT		254,266		218,001		734,100		635,837
OPERATING COSTS AND EXPENSES:								
Selling, general and administrative expenses		158,214		142,015		459,644		417,771
Depreciation and amortization expense		15,005		15,268		44,417		46,027
Total operating expenses		173,219		157,283		504,061		463,798
OPERATING INCOME		81,047		60,718		230,039		172,039
OTHER INCOME (EXPENSE):								
Interest expense, net		(11,786)		(13,997)		(38,816)		(39,008)
Other, net		824		5,360		88,594		7,956
Total other (expense) income		(10,962)		(8,637)		49,778		(31,052)
INCOME BEFORE INCOME TAXES		70,085		52,081		279,817		140,987
INCOME TAX EXPENSE		13,783		13,258		69,904		37,960
NET INCOME	\$	56,302	\$	38,823	\$	209,913	\$	103,027
Earnings per share, basic	\$	0.31	\$	0.21	\$	1.17	\$	0.57
Earnings per share, diluted	\$	0.31	\$	0.21	\$	1.16	\$	0.57
Weighted average common shares outstanding, basic		178,826		181,884		179,956		180,829
Weighted average common shares outstanding, diluted		180,528		183,022		181,286		181,760

### OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)(UNAUDITED)

2023 2022   CASH FLOWS FROM OPERATING ACTIVITIES: \$ 209,913 \$ 103,027   Adjustments to reconcile net income to net cash provided by operations: * *   Depreciation and amortization expense 46,423 49,723   Other non-cash adjustments 54,259 66,999   Changes in operating assets and liabilities: * *   Accounts receivable, net (5,075) (23,153)   Inventories (28,362) (52,749)   Accounts payable 50,726 129,859   Other (7,558) (49,614)   Net cash provided by operating activities 320,326 224,092   CASH FLOWS FROM INVESTING ACTIVITIES: * *   Acquisition of property and equipment (21,981) (17,111)   Business acquisitions, net of cash acquired (12,855) (87,315)   Other investing activities (5,889) -   Net cash used in investing activities (40,725) (104,426)   CASH FLOWS FROM FINANCING ACTIVITIES: * *   Purchase of company stock (175,108) -   Proceeds from warant exercises - 20,916   Other financing cash flows (12,190) (4,537)   Net cash (used in) provided by financing activities (12,190)		Nine Months End	led September 30,		
Net income     \$     209,913     \$     103,027       Adjustments to reconcile net income to net cash provided by operations:		 			
Adjustments to reconcile net income to net cash provided by operations:Depreciation and amortization expense46,423Other non-cash adjustments54,259Ghanges in operating assets and liabilities:Accounts receivable, net(5,075)Inventories(28,362)Other(28,362)Other(7,558)Other(7,558)Other(21,981)Net cash provided by operating activities320,326CASH FLOWS FROM INVESTING ACTIVITIES:(12,1981)Acquisition of property and equipment(12,855)Other investing activities(5,889)Net cash used in investing activities(40,725)Other financing cash flows(12,190)Other financing cash flows(12,190)Net cash used in investing activities-20,916(12,190)Other financing cash flows(12,190)Net cash used in provided by financing activities-20,916(12,190)Other financing cash flows(12,190)NET INCREASE IN CASH AND CASH EQUIVALENTS92,303NET INCREASE IN CASH AND CASH EQUIVALENTS92,303Cash and cash equivalents - beginning of the period294,186119,423-	CASH FLOWS FROM OPERATING ACTIVITIES:				
Depreciation and amortization expense     46,423     49,723       Other non-cash adjustments     54,259     66,999       Changes in operating assets and liabilities:     (5,075)     (23,153)       Accounts receivable, net     (5,075)     (23,153)       Inventories     (28,362)     (52,749)       Accounts payable     50,726     129,859       Other     (7,558)     (44),614)       Net cash provided by operating activities     320,326     224,092       CASH FLOWS FROM INVESTING ACTIVITIES:     (21,981)     (17,111)       Business acquisitions, net of cash acquired     (12,855)     (87,315)       Other investing activities     (40,725)     (104,426)       CASH FLOWS FROM FINANCING ACTIVITIES:       Acquisition of property and equipment     (21,981)     (17,111)       Business acquisitions, net of cash acquired     (12,855)     (87,315)       Other investing activities     (104,426)     (104,426)       CASH FLOWS FROM FINANCING ACTIVITIES:     —     —       Purchase of company stock     (175,108)     —       Proceeds from warant exercises     —	Net income	\$ 209,913	\$	103,027	
Other non-cash adjustments     54,259     66,999       Changes in operating assets and liabilities:     (5,075)     (23,153)       Accounts receivable, net     (5,075)     (23,153)       Inventories     (28,362)     (5,774)       Accounts payable     50,726     129,859       Other     (7,558)     (49,614)       Net cash provided by operating activities     320,326     224,092       CASH FLOWS FROM INVESTING ACTIVITIES:     (12,981)     (17,111)       Business acquisitions, net of cash acquired     (12,855)     (87,315)       Other investing activities     (5,889)        Net cash used in investing activities     (104,426)     (104,426)       CASH FLOWS FROM FINANCING ACTIVITIES:     -     20,916       Other investing activities     (104,426)     -       Vect cash used in investing activities     (175,108)        Purchase of company stock     -     20,916       Other financing cash flows     (12,190)     (45,327)       Net cash (used in) provided by financing activities     (187,298)     116,379       Net cash (used in) provided by financing act	Adjustments to reconcile net income to net cash provided by operations:				
Changes in operating assets and liabilities:Accounts receivable, net(5,075)Accounts receivable, net(5,075)Inventories(28,362)Accounts payable50,726Other(7,558)Other(7,558)Ket cash provided by operating activities320,326CASH FLOWS FROM INVESTING ACTIVITIES:(21,981)Acquisition of property and equipment(21,981)Met cash used in investing activities(5,889)Other investing activities(5,889)Other investing activities(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:(40,725)Other investing activities(175,108)Other investing activities(175,108)Other investing activities(175,108)Purchase of company stock(175,109)Proceeds from warrant exercises-Other financing cash flows(12,190)Other financing cash in provided by financing activities(187,228)NET INCREASE IN CASH AND CASH EQUIVALENTS92,303Cash and cash equivalents - beginning of the period294,186119,423	Depreciation and amortization expense	46,423		49,723	
Accounts receivable, net   (5,075)   (23,153)     Inventories   (28,362)   (52,749)     Accounts payable   50,726   129,859     Other   (7,558)   (49,614)     Net cash provided by operating activities   320,326   224,092     CASH FLOWS FROM INVESTING ACTIVITIES:   -   -     Acquisition of property and equipment   (21,981)   (17,111)     Business acquisitions, net of cash acquired   (12,855)   (87,315)     Other investing activities   (5,889)   -     Net cash used in investing activities   (104,426)   -     CASH FLOWS FROM FINANCING ACTIVITIES:   -   -     Purchase of company stock   (175,108)   -     Purchase of company stock   (175,108)   -     Proceeds from warrant exercises   -   20,916     Other financing cash flows   (12,190)   (4,537)     Net cash (used in) provided by financing activities   (18,7298)   16,379     Net cash (used in) provided by financing activities   92,303   136,045     CASH FLOWS FROM FINANCING ACHIVITIES:   -   224,186   119,423	Other non-cash adjustments	54,259		66,999	
Inventories(28,362)(52,749)Accounts payable50,726129,859Other(7,558)(49,614)Net cash provided by operating activities320,326224,092CASH FLOWS FROM INVESTING ACTIVITIES:Acquisition of property and equipment(21,981)(17,111)Business acquisitions, net of cash acquired(12,855)(87,315)Other investing activities(5,889)Net cash used in investing activities(40,725)(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:-20,916Other financing cash flows(12,190)(4,537)Net cash used in jorovided by financing activities(187,298)16,379Net cash (used in) provided by financing activities92,303136,045Cash and cash equivalents - beginning of the period2294,186119,423	Changes in operating assets and liabilities:				
Accounts payableC0,726129,859Other(7,558)(49,614)Net cash provided by operating activities320,326224,092CASH FLOWS FROM INVESTING ACTIVITIES:(21,981)(17,111)Business acquisitions, net of cash acquired(12,855)(87,315)Other investing activities(5,889)Net cash used in investing activities(40,725)(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:Purchase of company stock(175,108)Proceeds from warrant exercises-20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	Accounts receivable, net	(5,075)		(23,153)	
Other(7,558)(49,614)Net cash provided by operating activities320,326224,092CASH FLOWS FROM INVESTING ACTIVITIES:(21,981)(17,111)Business acquisitions, net of cash acquired(12,855)(87,315)Other investing activities(5,889)Net cash used in investing activities(40,725)(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:-20,916Purchase of company stock(175,108)Purchase of company stock(12,190)(4,537)Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	Inventories	(28,362)		(52,749)	
Net cash provided by operating activities224,092CASH FLOWS FROM INVESTING ACTIVITIES: Acquisition of property and equipment(21,981)(17,111)Business acquisitions, net of cash acquired(12,855)(87,315)Other investing activities(5,889)Net cash used in investing activities(40,725)(104,426)CASH FLOWS FROM FINANCING ACTIVITIES: Purchase of company stock-20,916Other financing cash flows(12,190)(4,537)Net cash used in provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	Accounts payable	50,726		129,859	
CASH FLOWS FROM INVESTING ACTIVITIES:Acquisition of property and equipment(21,981)(17,111)Business acquisitions, net of cash acquired(12,855)(87,315)Other investing activities(5,889)Net cash used in investing activities(40,725)(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:20,916Purchase of company stock(175,108)Proceeds from warrant exercises20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	Other	(7,558)		(49,614)	
Acquisition of property and equipment(21,981)(17,111)Business acquisitions, net of cash acquired(12,855)(87,315)Other investing activities(5,889)Net cash used in investing activities(40,725)(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:Purchase of company stock(175,108)Proceeds from warrant exercises20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	Net cash provided by operating activities	320,326		224,092	
Acquisition of property and equipment(21,981)(17,111)Business acquisitions, net of cash acquired(12,855)(87,315)Other investing activities(5,889)Net cash used in investing activities(40,725)(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:Purchase of company stock(175,108)Proceeds from warrant exercises20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423					
Business acquisitions, net of cash acquired(12,855)(87,315)Other investing activities(5,889)-Net cash used in investing activities(40,725)(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:Purchase of company stock(175,108)-Proceeds from warrant exercises-20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	CASH FLOWS FROM INVESTING ACTIVITIES:				
Other investing activities(5,889)—Net cash used in investing activities(40,725)(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:Purchase of company stock(175,108)—Proceeds from warrant exercises—20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	Acquisition of property and equipment	(21,981)		(17,111)	
Net cash used in investing activities(104,426)CASH FLOWS FROM FINANCING ACTIVITIES:(104,426)Purchase of company stock(175,108)Proceeds from warrant exercises–20,916(12,190)Other financing cash flows(12,190)Net cash (used in) provided by financing activities(187,298)NET INCREASE IN CASH AND CASH EQUIVALENTS92,303Cash and cash equivalents - beginning of the period294,186119,423	Business acquisitions, net of cash acquired	(12,855)		(87,315)	
CASH FLOWS FROM FINANCING ACTIVITIES:Purchase of company stock(175,108)Proceeds from warrant exercises-20,916Other financing cash flows(12,190)(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)NET INCREASE IN CASH AND CASH EQUIVALENTS92,303Cash and cash equivalents - beginning of the period294,186	Other investing activities	(5,889)		—	
Purchase of company stock(175,108)—Proceeds from warrant exercises—20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	Net cash used in investing activities	(40,725)		(104,426)	
Purchase of company stock(175,108)—Proceeds from warrant exercises—20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423					
Proceeds from warrant exercises—20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	CASH FLOWS FROM FINANCING ACTIVITIES:				
Proceeds from warrant exercises—20,916Other financing cash flows(12,190)(4,537)Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	Purchase of company stock	(175,108)		_	
Net cash (used in) provided by financing activities(187,298)16,379NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423		_		20,916	
NET INCREASE IN CASH AND CASH EQUIVALENTS92,303136,045Cash and cash equivalents - beginning of the period294,186119,423	Other financing cash flows	(12,190)		(4,537)	
Cash and cash equivalents - beginning of the period294,186119,423	Net cash (used in) provided by financing activities	(187,298)		16,379	
	NET INCREASE IN CASH AND CASH EQUIVALENTS	 92,303		136,045	
CASH AND CASH FOUNDALENTS, END OF BEDIOD \$ 386.489 \$ 255.468	Cash and cash equivalents - beginning of the period	294,186		119,423	
$\psi$ 500,403 $\psi$ 233,400	CASH AND CASH EQUIVALENTS - END OF PERIOD	\$ 386,489	\$	255,468	

### OPTION CARE HEALTH, INC. QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES (IN THOUSANDS)(UNAUDITED)

	Т	Three Months Ended September 30,			Nine Months Ended September 30,			
		2023		2022		2023		2022
Net income	\$	56,302	\$	38,823	\$	209,913	\$	103,027
Interest expense, net		11,786		13,997		38,816		39,008
Income tax expense		13,783		13,258		69,904		37,960
Depreciation and amortization expense		15,622		16,474		46,423		49,723
EBITDA		97,493		82,552		365,056		229,718
EBITDA adjustments								
Stock-based incentive compensation		9,235		4,005		22,908		12,581
Restructuring, acquisition, integration and other (1)		3,029		(934)		(74,383)		6,282
Adjusted EBITDA	\$	109,757	\$	85,623	\$	313,581	\$	248,581

(1) Restructuring, acquisition, integration and other for the nine months ended September 30, 2023 includes the Amedisys merger termination fee, net of merger-related expenses